期刊文献+

利拉鲁肽治疗初发2型糖尿病47例疗效分析 被引量:2

下载PDF
导出
摘要 选取2015年1月至2015年6月在大连大学附属中山医院内分泌科住院患者47例初发的肥胖2型糖尿病患者,应用利拉鲁肽降糖治疗12周,结果:空腹血糖2小时血糖糖化血红蛋白从体重、腰围Hs-CRP均明显下降肝功能、血脂、尿酸、尿微量蛋白/肌酐治疗前后无明显差异,P>0.05。结论:利拉鲁肽治疗初发肥胖2型糖尿病患者降糖治疗有效,显著降低体重,无低血糖发生。
出处 《实用糖尿病杂志》 2015年第6期15-17,共3页 Journal of Practical Diabetology
  • 相关文献

参考文献10

  • 1deKoning L,Merchant AT,Pogue J,et al. Waist circumferenceand waist-to-hip ratio as predictors of cardiovascular events : meta-re-gression analysis of prospective studies. Eur Heart J 2007 ; 28 (7 ):850-856.
  • 2deKoning L,Merchant AT,Pogue J,et al. Waist circumferenceand waist-to-hip ratio as predictors of cardiovascular events : meta-re-gression analysis of prospective studies. Eur Heart J 2007 ; 28 (7):850-856.
  • 3Malm-Erjefalt,Ekblom M,Brondsted L,et al. A randomised,double-blind, cross-over trial investigating the effect of liraglutide onthe absorption pharmacokinetics of concomitantly administered oraldrugs in healthy subjects. Diabetes 2008 ;57 (Suppl. 1) :434.
  • 4Nauck M, Pratley R, Brett J,et al. Adding liraglutide to exist-ing therapy produces greater improvement in glycemic control : evi-dence from a meta-analysis. Diabetes 2009 ;58( Suppl. 1) : A122.
  • 5Monami M, Dicembrini I, Marchionni N,et al. Effects of glu-cagon-like peptide-1 receptor agonists on body weight : a meta-analy-sis. Exp Diabetes Res 2012 ; 10 :672658-672666.
  • 6Pantalone KM,Faiman C. Liraglutide effective in the severelyinsulin-resistant patient with type 2 diabetes requiring U-500 insulin : acase report. Diabetes Technol Ther 2013 ;15(4) :342-343.
  • 7YuyaFujishima, Norikazu Maeda, Kana Inoue, et al. Efficacyof liraglutide,a glucagon-like peptide-1 ( GLP-1) analogue,on bodyweight,eating behavior,and glycemic control,in Japanese obese type 2diabetes. Cardiovascular Diabetology 2012;9( 11) :107-115.
  • 8Wing RR, Lang W, Wadden TA, et al. Look AHEAD Re-search Group : Benefits of modest weight loss in improving cardiovas-cular risk factors in overweight and obese individuals with type 2 dia-betes. Diabetes Care 2011 ;34(7) : 1481-1486.
  • 9Kawashima S, Matsuoka TA, Kaneto H, et al. Effect of alo-gliptin, pioglitazone and glargine on pancreatic p-cells in diabetic db/db mice. BiocheraBiophys Res Comxnun 2011 ;404( 1) :534 - 540.
  • 10张志红,杨刚毅,李伶,刘瑞,李钶,李生兵,陈文雯,朱伟,Guenther Boden.利拉鲁肽对RNAi介导的脂联素基因抑制ApoE基因敲除小鼠糖脂代谢的影响[J].中华内分泌代谢杂志,2010,26(10):871-874. 被引量:6

二级参考文献11

  • 1DeOre K,Greig NH,Holloway HW,et al.The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test.J Gerontol A Biol Sci Med Sci,1997,52:245-249.
  • 2Yang G,Li L,Tang Y,et al.Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats:possible role of the resistin and adiponectin.Biochem Biophys Res Commun,2006,339:1190-1196.
  • 3Samuel VT,Liu ZX,Qu X,et al.Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.J Biol Chem,2004,279:32345-32353.
  • 4Hansen I,Deacon CF,Orskov C,et al.Glucagon-like peptide-1 (7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase Ⅳ in the capillaries supplying the Ⅰ cells of porcine intestine.Endocrinology,1999,140:5356.
  • 5Liu X,Harada N,Yamane S,et al.Effects of long-term dipeptidyl peptidase-Ⅳ inhibition on body composition and glucose tolerance in high fat diet-fed mice.Life Sci,2009,84:876-881.
  • 6Vilsbφll T,Zdravkovic M,Le-Thi T,et al.Liraglutide,a long-acting human glucagon-like peptide-1 analog,given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.Diabetes Care 2007,30:1608-1610.
  • 7Kirsten R,Vossl PV,Carsten F,et al.Liraglutide,a long-acting glucagon-like peptide-1 analog,reduces body weight and food intake in obese candy-fed rats,whereas a dipeptidyl peptidase-Ⅳ inhibitor,vildagliptin,does not.Diabetes,2007,56:8-15.
  • 8李钶,杨刚毅,李伶,李清明,孟凡萍,唐毅,Guenther Boden.RNA干扰对脂联素在3T3-L1脂肪细胞中表达的影响[J].中国糖尿病杂志,2007,15(10):589-590. 被引量:3
  • 9孟凡萍,杨刚毅,李钶,李伶,齐晓亚,刘建雷,李荣.腺病毒载体介导的siRNA对3T3-L1细胞脂联素表达的影响[J].第三军医大学学报,2008,30(14):1312-1315. 被引量:5
  • 10高妍.调控β细胞,直击糖尿病——GLP-1及利拉鲁肽的基础与临床[J].中华内分泌代谢杂志,2009,25(6). 被引量:14

共引文献5

同被引文献12

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部